Interventional Neurology Devices Market Forecast 2020-2026

The Global Interventional Neurology Devices Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The report consists of trends that are anticipated to impact the growth of the Interventional Neurology Devices Market during the forecast period between 2020 and 2026. Evaluation of these trends is included in the report, along with their product innovations.

Get a PDF Copy of the Sample Report for free @ https://industrygrowthinsights.com/request-sample/?reportId=133707

The Report Covers the Following Companies:AbbottDePuy SynthesMedtronicStrykerTerumoAcandisBayerBoston ScientificBiosensors InternationalevonosMerit Medical SystemsMicroPort ScientificNeurosignPenumbraSpiegelbergSurtex Instruments

By Types:by ProductsCarotid Artery Angioplasty and StentingCarotid Artery StentsEmbolic Protection SystemsBalloon Occlusion DevicesAneurysm Coiling and Embolization DevicesFlow Diversion DevicesLiquid Embolic DevicesEmbolic coilsMicr-Support DevicesMicrocathetersby TechniquesAngioplasty & StentingNeurothrombectomyPre-operative Tumor EmbolizationVertebroplastyStroke Therapy

By Applications:Arteriovenous Malformation and FistulasCerebral AneurysmsSchemic StrokesIntracranial Atherosclerotic Disease

Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.

By Regions:

Grab Your Report at an Impressive Discount! Please click here @ https://industrygrowthinsights.com/ask-for-discount/?reportId=133707

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026

Important Facts about Interventional Neurology Devices Market Report:

What Our Report Offers:

Make an Inquiry of This Report @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=133707

About Industrygrowthinsights:Industrygrowthinsights has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473Email: [emailprotected]Website: https://Industrygrowthinsights.com

Read more here:
Interventional Neurology Devices Market 2020 Industry Size, Trends, Global Growth, Insights And Forecast Research Report 2025 - Aerospace Journal

Compelling advances in the ability to detect signs of consciousness in unconscious patients who have experienced traumatic brain injury (TBI) are leading to unprecedented changes in the field. There is now hope of improving outcomes and even sparing lives of patients who may otherwise have been mistakenly assessed as having no chance of recovery.

A recent key study represents a tipping point in the mounting evidence of the ability to detect"covert consciousness" in patients with TBI who are in an unconscious state. That research, published in The New England Journal of Medicine (NEJM) in June 2019, linked the promising signals of consciousness in comatose patients, detected only on imaging, with remarkable outcomes a year later.

"This was a landmark study," said Brian L. Edlow, MD, in a presentation on the issue of covert consciousness during the American Neurological Association's 2020 virtual annual meeting.

"Importantly, it is the first compelling evidence that early detection of covert consciousness also predicts 1-year outcomes in the Glasgow Outcome Scale Extended (GOSE), showing that covert consciousness in the ICU appears to be relevant for predicting long-term outcomes," said Edlow, who is associate director of the Center for Neurotechnology and Neurorecovery, Massachusetts General Hospital, in Boston.

The researchers showed that 15% of unconscious patients with acute brain injury in the study exhibited significant brain activity on EEG in response to stimuli that included verbal commands such as envisioning that they are playing tennis.

Although other studies have shown similar effects with task-based stimuli, the NEJM study further showed that a year later, the patients who had shown signs of covert consciousness, also called "cognitive motor dissociation" (CMD), were significantly more likely to have a good functional outcome, said the study's senior author, Jan Claassen, MD, director of critical care neurology at Columbia University, in New York City, who also presented during the ANA session.

"Importantly, a year later after injury, we found that 44% of patients with CMD and only 14% of non-CMD patients had a good functional outcome, defined as a GOSE score indicating a state where they can at least take care of themselves for 8 hours in a day," he said.

"[Whether] these patients in a CMD state represent a parallel state or a transitory state on the road to recovery remains to be shown," he said.

Jennifer Frontera, MD, a professor in the Department of Neurology at NYU Langone in New York City and co-moderator of the session, agreed that the research is "remarkable."

"Also, it is practical, since many could potentially apply and validate his algorithms, since EEG technology is portable and widely available," she told Medscape Medical News.

The research has helped push forward recommendations on the treatment of unconscious patients, Edlow said.

"This has led to a sea change in our field just over the last 2 years, with multiple guidelines published suggesting that it may be time for us to consider incorporating task-based fMRI and EEG techniques into our clinical assessment of patients with disorders of consciousness," Edlow said.

Among those updating their recommendations was the American Academy of Neurology, which revised guidelines on practice parameters for patients in a persistent vegetative state. Those guidelines had not been updated since 1995.

Although concluding that "no diagnostic assessment procedure had moderate or strong evidence for use," the guidelines acknowledge that "it is possible that a positive electromyographic (EMG) response to command, EEG reactivity to sensory stimuli, laser-evoked potentials, and the Perturbational Complexity Index can distinguish a minimally conscious state from vegetative state/unresponsive wakefulness syndrome (VS/UWS)."

Earlier this year, the European Academy of Neurology (EAN) followed suit with updated guidelines of its own.

In the EAN guideline, the academy's Panel on Coma, Disorders of Consciousness, recommends that task-based fMRI, EEG, and other advanced assessments be performed as part of a composite assessment of consciousness and that a patient's best performance or highest level of consciousness on any of those tests should be a reflection of their diagnosis, Edlow explained.

"What this means is that our field is moving toward a multimodal assessment of consciousness in the ICU as well as beyond, in the subacute to chronic setting, whereby the behavioral exam, advanced DG, and advanced MRI methods all also contribute to the diagnosis of consciousness," he said.

The gold standard for assessment of disorders of consciousness is the Coma Recovery Scale Revised, with 25-item scale for diagnosis, prediction of outcome, and assess potential treatment efficacy.

But much uncertainty can remain despite the assessment, Claassen said.

"Behavioral assessments of patients with acute brain injury are challenging because examinations fluctuate, and there's variability between assessors," he said. "Nevertheless, patients and their families demand guidance from us."

Edlow pointed out that the largest study to date of the causes of death among patients with TBI in the ICU underscores the need for better assessments.

The study of more than 600 patients at six level l trauma centers in Canada showed that 70% of patients who died in the ICU from TBI did so as the result of the withdrawal of life-sustaining therapy.

However, only about a half (57%) had an unreactive pupil, and only about a quarter (23.7%) had evidence of herniation on CT, findings that are commonly associated with a poor prognosis.

"What emerges from this is that the manner in which the clinicians communicated the prognosis to families was a primary determinant of decisions to withdraw life-sustaining therapy," Edlow said.

Edlow added a word of caution that the science is still far from perfect. He noted that for 25% of healthy patients who are given a motor imagery task, neuroimaging might not show a response, implying that the lack of a signal may not be conclusive.

He described the case of a patient who was comatose at the time she was scanned on day 3 after injury and who showed no responses to language, music, or motor imagery during the MRI, yet a year later, she was functionally independent, back in the workforce, and had very few residual symptoms from her trauma.

"So if a patient does not show a response, that does not prove the patient is not conscious, and it does not prove that the patient is likely to have a poor outcome," Edlow said.

Such cases underscore the need for more advances in understanding the inner workings of brain injury.

Heeding that call, Edlow and his colleagues are embarking on a trial of the effects of intravenous methylphenidate in targeting the stimulation of dopaminergic circuits within the subcortical ascending arousal network in patients with severe brain injuries.

"The scientific premise of the trial is that personalized brain network mapping in the ICU can identify patients whose connectomes are amenable to neuromodulation," Edlow and his colleague report in an article in Neurocritical Care.

The trial, called STIMPACT (Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness), is part of the newly launched Connectome-based Clinical Trial Platform, which the authors describe as "a new paradigm for developing and testing targeted therapies that promote early recovery of consciousness in the ICU."

Such efforts are essential, given the high stakes of TBI outcomes, Edlow said.

"Let's be clear about the stakes of an incorrect prognosis," he said. "If we're overly pessimistic, then a patient who could have potential for meaningful recovery will likely die in our ICU. On the other hand, if we are overly optimistic, then a patient could end up in a vegetative or minimally conscious state that he or she may never have found to be acceptable," he said.

Some ethicists in the field are recommending that patients be given access to the advanced techniques as a civil right, similar to the rights described in the Convention on the Rights of Persons With Disabilities, which was adopted by the United Nations in 2008, Edlow noted.

"So the question that we as clinicians are going to face moving forward from an ethical standpoint is, if we have access to these techniques, is it an ethical obligation to offer them now?" he said.

Edlow underscored the need to consider the reality that "there are profound issues relating to resource allocation and access to these advanced techniques, but we're going to have to consider this together as we move forward."

Edlow has received funding from the National Institutes of Health. Claassen is a minority shareholder with ICE Neurosystems. Frontera has disclosed no relevant financial relationships.

ANA 2020: 145th Annual Meeting of the American Neurological Association: Abstract 535, presented October 9, 2020.

For more Medscape Neurology news, join us on Facebook and Twitter.

Read the rest here:
'Landmark' Study Pushed Detection of Covert Consciousness in TBI - Medscape

Global Neurology EMR Software Market Research report 2020 provides detailed analysis of industry status and outlook of major regions based on of key players, countries, product types, and end industries. This research report offers the overall analysis of the segments such as market opportunities, import/export details, market dynamics, key manufacturers, growth rate, and key regions. Global Neurology EMR Software market research report consist information according to the manufacturers, regions, type, and application.

According to the report, the Neurology EMR Software market is set to grow at a CAGR of xx% over the forecast period (2019-2027) and exceed a value of US$ XX by the end of 2027. The global Neurology EMR Software market offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status.

Leading companies reviewed in the Neurology EMR Software Market report are: NueMDGreenway HealthAdvancedMDAthenahealthPrognoCIS by BizmaticsKareoAprima EHR SoftwareAzalea HealtheClinicalWorksCureMDChartLogic EHR SuiteDocLinks

Available Sample Report in PDF Version along with Graphs and Figures@ https://www.apexmarketsresearch.com/report/global-neurology-emr-software-market-by-product-type-649823/#sample

Covid-19 pandemics create the negative impact on the majority of the developed and developing economies around the globe. Report covers the income impact investigation, interruptions and new open doors in the gracefully chain, overhauled merchant scene blend, new open doors mapping, and others. Also offers the various solutions and recovery options to solve this COVID-19 pandemic.

Global Neurology EMR Software Market Segmentation by Type: Type IType II

Global Neurology EMR Software Market Segmentation by Applications:Medical FacilitiesResearch InstitutesOthers

Market Segmentation, By regions:

The report covers different geographical areas that are studied systematically and other profitable scenarios are offered to assist new entrants, leading market players, and investors to regulate emerging economies.

The global Neurology EMR Software research report focuses on the potential tradeoff between the quality and price; industry stakeholders which are actively leveraging the potential across the various applications, such as product design, quality control, maintenance, as well as consumer engagement among others.

Do enquire to get a strategic overview of the market, Access Research Methodology Prepared By Experts at: https://www.apexmarketsresearch.com/report/global-neurology-emr-software-market-by-product-type-649823/#inquiry

Important Points Covered by Report:

Access Full Report, here: https://www.apexmarketsresearch.com/report/global-neurology-emr-software-market-by-product-type-649823/

There are 13 Chapters to display the Global Neurology EMR Software market:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation overviewChapter 2: Market Competition by ManufacturersChapter 3: Production by RegionsChapter 4: Consumption by RegionsChapter 5: Production, By Types, Revenue and Market share by TypesChapter 6: Consumption, By Applications, Market share (%) and Growth Rate by ApplicationsChapter 7: Complete profiling and analysis of ManufacturersChapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expensesChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Market ForecastChapter 13: Neurology EMR Software Research Findings and Conclusion, Appendix, methodology and data source.

Read more:
Impact of Covid-19 Global Neurology EMR Software Market (2020 To 2027) | NueMD, Greenway Health, AdvancedMD, Athenahealth, PrognoCIS by Bizmatics -...

Technavio has been monitoring the neurology devices market and it is poised to grow by $ 9.02 bn during 2020-2024, progressing at a CAGR of almost 12% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005783/en/

Technavio has announced its latest market research report titled Global Neurology Devices Market 2020-2024 (Graphic: Business Wire)

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19 Impacts

Frequently Asked Questions:

What are the major trends in the market? Increasing adoption of wearable neurology devices is a major trend driving the growth of the market

At what rate is the market projected to grow? The year-over-year growth for 2020 is estimated at 11.50% and the incremental growth of the market is anticipated to be $ 9.02 bn

Who are the top players in the market? Abbott Laboratories, B. Braun Melsungen AG, Becton, Dickinson and Co., Boston Scientific Corp., Johnson & Johnson Services Inc., Medtronic Plc, MicroPort Scientific Corp., Nihon Kohden Corp., Penumbra Inc., and Stryker Corp., are some of the major market participants

What is the key market driver? The increasing prevalence of the neurological disorders is one of the major factors driving the market

How big is the North America market? The North America region will contribute 42% of the market share

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Abbott Laboratories, B. Braun Melsungen AG, Becton, Dickinson and Co., Boston Scientific Corp., Johnson & Johnson Services Inc., Medtronic Plc, MicroPort Scientific Corp., Nihon Kohden Corp., Penumbra Inc., and Stryker Corp. are some of the major market participants. The increasing prevalence of the neurological disorders will offer immense growth opportunities. To make most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Story continues

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Neurology Devices Market 2020-2024: Segmentation

Neurology Devices Market is segmented as below:

Product

Geography

Asia

Europe

North America

ROW

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40120

Neurology Devices Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The neurology devices market report covers the following areas:

Neurology Devices Market Size

Neurology Devices Market Trends

Neurology Devices Market Industry Analysis

This study identifies increasing adoption wearable neurology devices as one of the prime reasons driving the neurology devices market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Neurology Devices Market 2020-2024: Key Highlights

CAGR of the market during the forecast period 2020-2024

Detailed information on factors that will assist neurology devices market growth during the next five years

Estimation of the neurology devices market size and its contribution to the parent market

Predictions on upcoming trends and changes in consumer behavior

The growth of the neurology devices market

Analysis of the markets competitive landscape and detailed information on vendors

Comprehensive details of factors that will challenge the growth of neurology devices market vendors

Table of Contents:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Neurostimulation devices - Market size and forecast 2019-2024

Interventional neurology devices - Market size and forecast 2019-2024

Neurosurgery devices - Market size and forecast 2019-2024

Cerebrospinal fluid management devices - Market size and forecast 2019-2024

Others - Market size and forecast 2019-2024

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America - Market size and forecast 2019-2024

Europe - Market size and forecast 2019-2024

Asia - Market size and forecast 2019-2024

ROW - Market size and forecast 2019-2024

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Technological advances and new product launches

Strong penetration of wearable neurology devices

Growing medical tourism in emerging economies

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Abbott Laboratories

B. Braun Melsungen AG

Becton, Dickinson and Co.

Boston Scientific Corp.

Johnson & Johnson Services Inc.

Medtronic Plc

MicroPort Scientific Corp.

Nihon Kohden Corp.

Penumbra Inc.

Stryker Corp.

PART 14: APPENDIX

PART 15: EXPLORE TECHNAVIO

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201021005783/en/

Contacts

Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.com Website: http://www.technavio.com/

View original post here:
Neurology Devices Market | Increasing Prevalence Of The Neurological Disorders to boost the Market Growth | Technavio - Yahoo Finance

Neurological diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) cause damage to nerve fibers that cant be reversed. Now, scientists at Ohio State University and the University of Michigan have discovered an immune cell they believe could be harnessed to partially reverse this damage and slow MS, ALS and other neurodegenerative disorders.

By studying mouse models, the researchers discovered a new type of white blood cell known as a granulocyte. Its similar to a neutrophilan infection-fighting white blood cellbut it secretes growth factors that helped axons of the central nervous system regenerate, the team reported in the journal Nature Immunology. They identified a subset of human immune cells with similar properties, they said.

The ability of this subset of granulocyte to stimulate the regrowth of severed nerve fibers is "really unprecedented," said Benjamin Segal, M.D., professor and chair of neurology at Ohio State College of Medicine and co-director of the Wexner Medical Center's Neurological Institute, in a statement. "In the future, this line of research might ultimately lead to the development of novel cell based therapies that restore lost neurological functions across a range of conditions."

RELATED: How the brain's immune cells could guide treatment of neurodegenerative diseases

The team observed that the newly discovered granulocytes were similar to immature neutrophils. To test whether the granulocytes might have therapeutic powers, the researchers injected them into mice with injured optic nerves or broken nerve fibers. Those animals regrew nerve fibers, while mice injected with mature neutrophils did not.

The notion that immunotherapy might offer solutions to brain diseases is a popular one in neurological research. Last year, Stanford University researchers described a subpopulation of CD8 T cells that could be boosted with a peptide to relieve MS symptoms in mice.

And just last month, researchers led by Mount Sinais Icahn School of Medicine reported that immune cells called microglia can tamp down excessive neuron activity in diseases such as Alzheimers and Huntingtons. Targeting microglia in neurodegenerative diseases is also the focus of startup Tranquis Therapeutics, which launched with $30 million in capital this summer.

The next step for the Ohio State and University of Michigan researchers is to collect the neuro-enhancing granulocytes they discovered and figure out how to enhance them in the lab. Ultimately, they hope to determine whether the cells could be injected into patients to reverse damage to the central nervous system.

Such an immunotherapy could be useful not just for treating diseases like MS and ALS, but also for treating traumatic injuries to the brain and spine, they suggested.

Original post:
Newly discovered immune cell offers path to treating ALS, MS and other brain diseases - FierceBiotech

Global Interventional Neurology Device Market Report Details Out Market Overview, Market Valuation, And Future Market Prospective

The Interventional Neurology Device markets growth and development is significantly skyrocketing due to the current modernization and innovative futuristic scopes. TheInterventional Neurology Device marketreport mentions all the details regarding the latest techniques that are followed in order to meet the customers demand and supply. Some of the most important and intricate data including the market share, supply and demand statistics, growth factors, and investment dynamics are mentioned in such a clear format that the clients can grab the growth and development facets from the dossier for a piece of better global market knowledge. The current report helps open new doors for the global Interventional Neurology Device market. Some of the vital players W.L. Gore & Associates, Microport Scientific Corporation, Medikit Co., Ltd., Medtronic, Penumbra, Inc., Merit Medical Systems, Inc, Terumo Corporation, Stryker, Johnson and Johnson that are at present dominating the global platform include.

Click here for the free sample copy of the Interventional Neurology Device Market report

Key objectives that motivate the procurement of this report:-

To study and analyze the global valuation (size, revenue,& volume) based on key regions/countries, product type, application, and history data To understand the breakdown structure of Interventional Neurology Device market Studying the market valuation, competitive landscape, and recent development plans help gain better insight of the market Analyzing ample information such as opportunities, drivers, industry-specific challenges and risks that prompt the Interventional Neurology Device market growth To study competitive advances such as expansions, agreements, new product launches, and acquisitions, mergers among the key market players To analyze the strategic business strategies and its impact on the market growth rate

The informative research report has summarized even the government stringent rules and regulations, market segmentation, and expert practices. The transparency portrayed in the current dossier is bliss for both clients and other business players. Along with the current and forecast trends, even the historical details are penciled down for grasping a better outlook of the entire market on a global scale. The most important part is the regional segmentation North America (United States, Canada and Mexico), Europe (Germany, UK, France, Italy, Russia and Turkey etc.), Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam), South America (Brazil, Argentina, Columbia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) of the Interventional Neurology Device market as the scale of growth across the globe can easily be depicted and understood.

Read Detailed Index of full Research Study at::https://www.marketdataanalytics.biz/global-interventional-neurology-device-market-report-2020-by-key-71477.html

An Overview About the Table of Contents:

Global Interventional Neurology Device Market Overview Target Audience for the Interventional Neurology Device Market Economic Impact on the Interventional Neurology Device Market Global Interventional Neurology Device Market Forecast Business Competition by Manufacturers Production, Revenue (Value) by Region Production, Revenue (Value), Price Trend by Type Market Analysis by Application Cost Analysis Industrial Chain, Sourcing Strategy, and Downstream Buyers Marketing Strategy Analysis, Distributors/Traders Market Effect Factors Analysis

The Interventional Neurology Device market report has a paragraph dedicated to the market segmentation {Carotid artery angioplasty & stenting, Embolization & coiling, Neurothrombectomy Devices}; {Treatment of Cerebral Aneurysms, Treatment of Cerebral Vasospasm, Vertebroplasty} mentioned in a bifurcated form for an easy grip on the global market. From the current contextual report, the clients get knowledge about the trade and industry, stringent industrial practices, profit and loss statistics, growth benefits, product demand and supply, economic fluctuations, and future market scope. The current research report basically aims towards only providing the customers with the entire market study and ongoing trends with just a single click in a simple and brief format.

Enquire Here Get customization & check discount for report@https://www.marketdataanalytics.biz/global-interventional-neurology-device-market-report-2020-by-key-71477.html#inquiry-for-buying

Why Choose Market Data Analytics reports?

Our analysts use latest market research techniques to create the report Market reports are curated using the latest market research and analytical tools Customization of report is possible as per the requirement Our team comprises of expertise and highly trained analysts Quick responsive customer support for domestic and international clients

Visit link:
Global Interventional Neurology Device Market 2020 COVID-19 Updated Analysis By Product (Carotid artery angioplasty & stenting, Embolization &...

Researchers are hoping a new cell discovery will lead to strides when it comes to future treatments for degenerative neurological disorders like ALS and multiple sclerosis.

"If this translates to the clinic and it actually is successful, it'll be a game-changer," said Dr. Benjamin Segal.

For more than 30 years as a neurologist, Dr. Segal has watched patients slowly succumb to disorders like multiple sclerosis. But now, he and a team at Ohio State University's Wexner Medical Center say they've discovered a new type of immune cells tested in mice, that they hope will lead to new treatments.

The treatments will be not only for those with degenerative neurological disease, but also for people suffering from brain or spinal cord damage, and even stroke.

"What we're all pursuing is better ways to make our patients function better and to reclaim lost skills and abilities," said Dr. Segal.

He says the cell tested in mice can save dying nerve cells and stimulate re-growth when nerve fibers are damaged. Dr. Segal says they've also identified an immune cell line in humans with similar characteristics that promotes nervous system repair.

The next step is to harness this cell in the lab. Researchers are hoping to one day be able to inject the cells into patients.

"There's really a tremendous potential with this new approach."

Link:
Cell discovery could lead to future treatments for neurological disorders - 6 On Your Side

Meet the Doctors of Memorial Hermann The Woodlands Medical Center who share information and experience on Deep Brain Stimulation, a surgical treatment option for patients suffering from Parkinsons disease and essential tremors.

Watch the video below with the Hello Woodlands interview with Dr. Allison Boyle and Dr. Saman Javedan:

Video produced by Rod Prado and Jennifer Bruse of Hello Woodlands

Dr. Allison Boyle is a board-certified neurologist specializing in neurology and movement disorders. Dr. Boyle is certified in botulinum toxin injections for dystonia, muscle spasm, sialorrhea or tremor; intrathecal baclofen pump therapy for the control of significant or severe spastic or dystonic tone; deep brain stimulation therapies for the control of tremor, signs and symptoms of Parkinsons disease and focal, segmental or generalized dystonia; and lumbar punctures.

Dr. Saman Javedan is a board-certified neurosurgeon and is board certified by the American Board of Neurological Surgery (ABNS). His areas of expertise include complex cranial tumors, complex spinal tumors, spinal reconstruction, spinal fusions, minimally invasive spine surgery, movement disorders, deep brain stimulation (DBS) and stereotactic radiosurgery (SRS).

Memorial Hermann-Texas Medical Center was the first hospital in Texas to implant the Food and Drug Administration (FDA) approved Percept PC Deep Brain Stimulation system by Medtronic in patients with neurologic disorders. With the investment of new technology and experienced doctors, the procedure is now available at Memorial Hermann The Woodlands Medical Center. The first-of-its-kind neurostimulator uses BrainSense Technology and has the ability to capture and record the users brain signals while delivering therapy to patients with neurologic disorders associated with such conditions as Parkinsons disease, essential tremor, dystonia, epilepsy or obsessive-compulsive disorder.

Patients undergo the deep brain stimulation system implantation in two phases over two hospital visits. During the first visit, the patient undergoes surgery to have electrodes implanted in their brain. On the patients second visit, connecting wires and neurostimulator is implanted.

Deep brain stimulation is a surgical treatment option for patients suffering from Parkinsons disease and other movement disorders. Through a small pacemaker-like device, the brain is sent mild electrical signals to a targeted area in the brain related to the symptoms of a neurological disorder. The signals help reorganize the brains electrical impulses and results in improved symptoms for many neurological conditions.

For more information on deep brain stimulation treatment at Memorial Hermann The Woodlands Medical Center visit http://neuro.memorialhermann.org/conditions-treatments/deep-brain-stimulation/.

Advertisement

Read the original here:
Meet the Doctor: Deep Brain Stimulation at Memorial Hermann The Woodlands - hellowoodlands.com

PM2.5 pollution was significantly associated with an increased risk of hospital admissions for several neurological disorders, including Parkinsons disease, Alzheimers disease, and other dementias, in a long-term study of more than 63 million older US adults, led by researchers at Harvard T.H. Chan School of Public Health.

The study, conducted with colleagues at Emory Universitys Rollins School of Public Health and Columbia Universitys Mailman School of Public Health, is the first nationwide analysis of the link between fine particulate (PM2.5) pollution and neurodegenerative diseases in the US. The researchers leveraged an unparalleled amount of data compared to any previous study of air pollution and neurological disorders.

The open-access study is published in the journal The Lancet Planetary Health.

The 2020 report of the Lancet Commission on dementia prevention, intervention, and care has added air pollution as one of the modifiable risk factors for these outcomes. Our study builds on the small but emerging evidence base indicating that long-term PM2.5 exposures are linked to an increased risk of neurological health deterioration, even at PM2.5 concentrations well below the current national standards.

Xiao Wu, doctoral student in biostatistics at Harvard Chan School and co-lead author

Researchers looked at 17 years worth (2000-2016) of hospital admissions data from 63,038,019 Medicare recipients in the US and linked these with estimated PM2.5 concentrations by zip code.

Taking into account potential confounding factors such as socioeconomic status, they found that, for each 5 microgram per cubic meter of air (g/m3) increase in annual PM2.5 concentrations, there was a 13% increased risk for first-time hospital admissions both for Parkinsons disease and for Alzheimers disease and related dementias.

This risk remained elevated even below supposedly safe levels of PM2.5 exposure, which, according to current US Environmental Protection Agency standards, is an annual average of 12 g/m3 or less.

Women, white people, and urban populations were particularly susceptible, the study found. The highest risk for first-time Parkinsons disease hospital admissions was among older adults in the northeastern US For first-time Alzheimers disease and related dementias hospital admissions, older adults in the Midwest faced the highest risk.

Our US-wide study shows that the current standards are not protecting the aging American population enough, highlighting the need for stricter standards and policies that help further reduce PM2.5 concentrations and improve air quality overall.

Antonella Zanobetti, principal research scientist in Harvard Chan Schools Department of Environmental Health and co-senior author

This study was supported by the Health Effects Institute (4953-RFA14-3/16-4), the National Institute of Environmental Health Sciences (NIEHS R01 ES024332, R01 ES028805, R21 ES028472, P30 ES009089, P30 ES000002), the National Institute on Aging (NIA/NIH R01 AG066793-01, P50 AG025688), and the HERCULES Center (P30ES019776). Research described in this article was done under contract to the Health Effects Institute, an organization jointly funded by the US Environmental Protection Agency (assistance award number R-83467701) and some motor vehicle and engine manufacturers.

Resources

Liuhua Shi, Xiao Wu, Mahdieh Danesh Yazdi, Danielle Braun, Yara Abu Awad, Yaguang Wei, Pengfei Liu, Qian Di, Yun Wang, Joel Schwartz, Francesca Dominici, Marianthi-Anna Kioumourtzoglou, Antonella Zanobetti (2020) Long-term effects of PM2.5 on neurological disorders in the American Medicare population: a longitudinal cohort study, The Lancet Planetary Health doi: 10.1016/S2542-5196(20)30227-8

View post:
Study finds significant link between PM2.5 pollution and neurological disorders in US - Green Car Congress